Abstract

Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study

Arch Dis Child. 2020 Oct;105(10):957-963.doi: 10.1136/archdischild-2019-317823. Epub 2020 May 18.

Gareth J Walker 1 2, Neil Chanchlani 2 3, Amanda Thomas 1 2, Simeng Lin 1 2, Lucy Moore 4, Neel M Heerasing 1 2, Peter Hendy 1 2, Mohamed Abdelrahim 1, Sean Mole 1, Mandy H Perry 5, Timothy J Mcdonald 4 5, Claire M Bewshea 2, James W Hart 3, Richard K Russell 6, Tariq Ahmad 1 2, James R Goodhand 1 2, Nicholas A Kennedy 7 2

  • 1Gastroenterology, Royal Devon and Exeter Hospital, Exeter, UK.
  • 2Exeter IBD Pharmacogenetics, University of Exeter Medical School, Exeter, UK.
  • 3Paediatrics, Royal Devon and Exeter Hospital, Exeter, UK.
  • 4The College of Medicine & Health, University of Exeter, Exeter, UK.
  • 5Biochemistry, Royal Devon and Exeter Hospital, Exeter, UK.
  • 6Paediatric Gastroenterology, The Hospital For Sick Children, Edinburgh, UK.
  • 7Gastroenterology, Royal Devon and Exeter Hospital, Exeter, UK nick.kennedy1@nhs.net.

 
     

Author information

Abstract

Objective: To determine the diagnostic accuracy of calprotectin to diagnose inflammatory bowel disease (IBD) in children in whom general practitioners (GPs) suspected IBD.

Design: Prospective observational cohort study of a new calprotectin-based primary care referral pathway.

Setting: 48 GP practices and gastroenterology secondary care services at the Royal Devon and Exeter NHS Foundation Trust in the South-West of England, UK.

Patients: 195 children aged between 4 and 18 years referred on the pathway between January 2014 and August 2017 for investigation of gastrointestinal symptoms were included.

Interventions: Primary-care-driven faecal calprotectin testing. Primary and secondary care records over 12 months from the point of calprotectin testing were used as the reference standard.

Main outcome measures: Diagnostic accuracy of calprotectin testing to detect IBD.

Results: 7% (13/195) tested patients were diagnosed with IBD. Using our prespecified cut-off of 100 µg/g, calprotectin had a diagnostic accuracy of 91% (95% CI 86% to 95%) with a sensitivity for distinguishing IBD from non-IBD of 100% (95% CI 75% to 100%), a specificity of 91% (95% CI 85% to 94%), a positive predictive value of 43% (95% CI 25% to 63%) and a negative predictive value of 100% (95% CI 98% to 100%). Calprotectin testing had no effect on the time to diagnosis, but a negative test contributed to saved referrals and was associated with fewer diagnostic tests in secondary care.

Conclusions: Calprotectin testing of children with suspected IBD in primary care accurately distinguishes IBD from a functional gut disorder, reduces secondary care referrals and associated diagnostic healthcare utilisation.

© Copyright 2013-2021 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.